The Lancet Haematology Commission on global female health and haematology draws on evidence from clinical care, research, public health, and policy to identify gaps that delay diagnosis or lead to inconsistent care for women and girls across menstruation, pregnancy, the postpartum period, and later life. Its ten proposed actions include faster diagnosis, screening for heavy menstrual bleeding and iron deficiency, stronger postpartum haemorrhage and thrombosis care, and equitable representation of women in research and clinical guidance.
Key findings
- Official institutional summaries report that women with bleeding disorders may wait about 14–16 years for diagnosis, compared with roughly two years for men, partly because heavy menstrual bleeding is often normalised rather than investigated.
- Proposed actions include routine assessment of menstrual bleeding and iron deficiency, standardised postpartum-haemorrhage protocols, and individualised thrombosis care during pregnancy and the postpartum period.
- The Commission calls for equitable representation of women in drug studies and faster incorporation of women-specific evidence into diagnostic and treatment guidelines.
- Its life-course framework spans menstruation, contraception, pregnancy, postpartum care, and ageing, while linking clinical outcomes to socioeconomic conditions and access to care.
- The ten recommendations address care delivery, research, education, and policy, but their effect will depend on implementation capacity, referral systems, resources, and measurable follow-up.
Why this matters globally
The report’s global significance lies in turning broad concern about women’s health into an actionable agenda linking clinical care, research, and policy. A 36-author network spanning at least 14 countries and the Commission’s launch at ISTH 2026 give the recommendations a pathway into professional debate, guidelines, and health systems. However, Commission recommendations do not all carry the same evidentiary strength, and their value must ultimately be judged by implementation outcomes such as shorter diagnostic delays, reduced iron deficiency, safer postpartum care, and fewer thrombotic complications.
Thai researcher contribution
Associate Professor Kochawan Boonyawat of the Division of Haematology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, is a Commission co-author. Crossref and OpenAlex place her as a middle author rather than a corresponding author, and her Thai affiliation is corroborated by Mahidol University’s expert profile. Her participation brings Thai haematology and health-system experience into an international recommendations network, but the available metadata does not assign individual recommendations to her, so no more specific contribution should be inferred.
Limitations to consider
This is a Commission and policy roadmap, not a randomised trial or a single-effect systematic estimate. The DOI and authorship are verifiable, but Crossref and OpenAlex did not provide an abstract at the time of review and the full article is not open access; therefore, numerical claims and recommendations were also checked against official institutional and professional-society releases. Citation and FWCI values are very early signals because the article has only just appeared and must not be treated as quality scores. Implementation will also depend on resources, culture, referral capacity, and national context.